 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ALN-SOD / Alnylam, Regeneron
First-in-human study design to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ascending doses of ALN-SOD in patients with amyotrophic lateral sclerosis and SOD1 variants (Poster Hall at the Palais de Congres Montreal; 517b/c) - Nov 7, 2024 - Abstract #ALSMND2024ALS_MND_576;
This FIH study will provide information about the safety, tolerability, pharmacokinetics, and pharmaco-dynamics of ALN-SOD in participants with SOD1-ALS. The results will guide selection of dosing regimens to assess in the subsequent clinical development program.
- || ALN-SOD / Alnylam, Regeneron
Enrollment open: First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS) (clinicaltrials.gov) - Sep 19, 2024
P1, N=42, Recruiting, Sponsor: Regeneron Pharmaceuticals
The results will guide selection of dosing regimens to assess in the subsequent clinical development program. Not yet recruiting --> Recruiting
- || ALN-SOD / Alnylam, Regeneron
New P1 trial: First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS) (clinicaltrials.gov) - Apr 7, 2024
P1, N=42, Not yet recruiting, Sponsor: Regeneron Pharmaceuticals